Novartis gets Leqvio FDA approval for reducing bad cholesterol levels
Novartis has secured approval from the US Food and Drug Administration (FDA) for its small interfering RNA (siRNA) therapy Leqvio (inclisiran) for its use in ... Read More
Alnylam, Dicerna form RNAi collaboration for alpha-1 liver disease
Alnylam Pharmaceuticals and Dicerna Pharmaceuticals are joining forces to develop and commercialize ribonucleicacid interference therapies (RNAi therapeutics) for the treatment of alpha-1 antitrypsin deficiency-associated liver ... Read More